Press Release

Article

Fox Chase Cancer Center Welcomes Dr Simon Sung

Fox Chase Cancer Center is pleased to announce the hiring of Simon Sung, MD, as an associate professor in the Department of Pathology.

Simon Sung, MD

Simon Sung, MD

Fox Chase Cancer Center is pleased to announce the hiring of Simon Sung, MD, as an associate professor in the Department of Pathology.

Prior to coming to Fox Chase, Sung was an assistant professor in the Department of Pathology and Cell Biology at Columbia University Irving Medical Center in New York from August 2022 through February 2024 and from July 2018 through October 2020. He was also an assistant professor and associate director of the Cytology Fellowship Program in the Department of Pathology at Montefiore Medical Center, the university hospital for the Albert Einstein College of Medicine in Bronx, New York.

Sung earned his undergraduate degree from the Peabody Institute of the Johns Hopkins University and his medical degree from Columbia University Vagelos College of Physicians and Surgeons.

He completed an anatomic pathology residency at Columbia University Medical Center - New York Presbyterian Hospital and a fellowship in cytopathology at Weill Cornell Medical College - New York Presbyterian Hospital. He also completed a fellowship in general surgical pathology at Columbia University Medical Center.

Sung has authored over 20 peer-reviewed articles in such journals as Cancer Cytopathology, Diagnostic Cytopathology, the European Journal of Neuroscience, and the American Journal of Neuroradiology. He was awarded the National Institutes of Health Summer Research Grant in 2010, the Sigmund L. Wilens Prize for Excellence in Pathology in 2013, and the Intersociety Council for Pathology Information Trainee Travel Award in 2016.

He is currently a member of the United States and Canadian Academy of Pathology, the American Society of Cytopathology, the American Society for Clinical Pathology, and the College of American Pathologists.

Related Videos
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.